Zhi Tong Cai Jing·2026-03-28 07:20Core Insights - Rongchang Biologics reported a revenue of RMB 3.242 billion for the year ending December 31, 2025, representing a year-on-year increase of 89.55% [2] - The company achieved a net profit attributable to shareholders of RMB 710 million, a significant turnaround from a loss of RMB 1.468 billion in the previous year [2] - Earnings per share stood at RMB 1.29 [2] Product Performance - The product sales revenue for the year was approximately RMB 2.307 billion, up 35.8% from RMB 1.699 billion in the previous year, driven by strong sales of its immunotherapy product Tai'aisip (RC18) and anti-tumor product Aidexi (RC48) [2] - Tai'aisip, the world's first innovative dual-target biologic for SLE treatment, was approved for sale in March 2021 and included in the national medical insurance drug list in December 2021, with successful renewals in 2023 and 2025 [2] - As of December 31, 2025, Tai'aisip has been approved for use in over 1,200 hospitals [2] Market Access and Strategy - Aidexi was approved for sale in June 2021 and included in the national medical insurance drug list for treating HER2-positive advanced gastric cancer by the end of 2021, with additional indications for HER2-positive urothelial carcinoma added in January 2023 [3] - Aidexi has also successfully renewed its inclusion in the medical insurance list for both indications by the end of 2025, with approval for use in over 1,050 hospitals [3] - The company plans to enhance product accessibility through targeted marketing strategies, engaging with key opinion leaders and physicians to establish a strong market presence and differentiate its products [3]